Nvidia and Eli Lilly announced a five‑year partnership to create a Co‑Innovation AI Lab backed by up to $1 billion to accelerate drug discovery through large‑scale compute and model development. Jensen Huang (Nvidia) and Lilly CEO David Ricks described the lab as infrastructure for building and deploying AI models trained on proprietary biomedical data and large compute resources. Nvidia also detailed a broader slate of industry collaborations at JPM—alliances with Thermo Fisher, Natera and other lab and diagnostics companies—to embed accelerated computing and AI pipelines into discovery and laboratory infrastructure. Executives said partnerships will cover compute, model co‑development and lab automation to cut early discovery timelines and scale predictive biology. Speakers emphasized investments in infrastructure, data partnerships and bio‑compute workflows rather than single‑product outcomes. The moves incorporate both raw compute and co‑design of software and models aimed at moving AI from prototyping to routine R&D applications.